People: Parithosh K. Tungaturthi, Ph.D., Patent Agent

Photo of Parithosh K. Tungaturthi, Ph.D., Patent Agent

Parithosh K. Tungaturthi, Ph.D.

Patent Agent

Washington, D.C.
Direct: (202) 828-3547
0

Parithosh K. Tungaturthi is a patent agent in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington, D.C. office. Dr. Tungaturthi’s practice focuses on the pharmaceutical and biotechnology industries and his expertise lies in the areas of patent portfolio creation and management, IP strategy development, patent landscape analysis, product lifecycle management, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions. Dr. Tungaturthi’s practice also includes active involvement in Paragraph IV litigation strategies, Hatch-Waxman litigation, and FDA Regulatory and Compliance matters.

Dr. Tungaturthi has significant expertise in a broad range of disciplines including pharmaceuticals, active pharmaceutical ingredients, formulations, drug delivery, organic and inorganic chemistry, molecular biology, antibody engineering and therapeutics, cancer immunology, molecular diagnostics, genetic engineering, stem cell technology, vaccines, medical devices, plant breeding and plant biotechnology. He also has experience in nanotechnology, polymer chemistry, biomaterial, and biofuels.

In addition, Dr. Tungaturthi handles trademark matters, including trademark application preparation, filing and prosecution, trademark search, and drafting trademark clearance reports.

Prior to joining the firm, Dr. Tungaturthi worked at prominent law firms in the Washington, D.C. area and served as a Patent Examiner at the U.S. Patent and Trademark Office (USPTO).

Dr. Tungaturthi earned his J.D. from The University of Baltimore School of Law. He received his Ph.D. in Molecular Biology and Immunology from Thomas Jefferson University and is a graduate of Louisiana State University, where he received his B.S. in Microbiology and conducted research in Organic Chemistry. Dr. Tungaturthi’s undergraduate and graduate research studies have been published in peer-reviewed scientific journals.

Prior to entering the field of intellectual property law, Dr. Tungaturthi served as a post-doctoral research fellow in the HIV and AIDS Malignancy Branch of National Cancer Institute at the National Institutes of Health. He was also a research associate in the analytical chemistry division of a start-up biotech company.

Parithosh K. Tungaturthi is a patent agent in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington, D.C. office. Dr. Tungaturthi’s practice focuses on the pharmaceutical and biotechnology industries and his expertise lies in the areas of patent portfolio creation and management, IP strategy development, patent landscape analysis, product lifecycle management, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions. Dr. Tungaturthi’s practice also includes active involvement in Paragraph IV litigation strategies, Hatch-Waxman litigation, and FDA Regulatory and Compliance matters.

Dr. Tungaturthi has significant expertise in a broad range of disciplines including pharmaceuticals, active pharmaceutical ingredients, formulations, drug delivery, organic and inorganic chemistry, molecular biology, antibody engineering and therapeutics, cancer immunology, molecular diagnostics, genetic engineering, stem cell technology, vaccines, medical devices, plant breeding and plant biotechnology. He also has experience in nanotechnology, polymer chemistry, biomaterial, and biofuels.

In addition, Dr. Tungaturthi handles trademark matters, including trademark application preparation, filing and prosecution, trademark search, and drafting trademark clearance reports.

Prior to joining the firm, Dr. Tungaturthi worked at prominent law firms in the Washington, D.C. area and served as a Patent Examiner at the U.S. Patent and Trademark Office (USPTO).

Dr. Tungaturthi earned his J.D. from The University of Baltimore School of Law. He received his Ph.D. in Molecular Biology and Immunology from Thomas Jefferson University and is a graduate of Louisiana State University, where he received his B.S. in Microbiology and conducted research in Organic Chemistry. Dr. Tungaturthi’s undergraduate and graduate research studies have been published in peer-reviewed scientific journals.

Prior to entering the field of intellectual property law, Dr. Tungaturthi served as a post-doctoral research fellow in the HIV and AIDS Malignancy Branch of National Cancer Institute at the National Institutes of Health. He was also a research associate in the analytical chemistry division of a start-up biotech company.

Education

  • J.D., The University of Baltimore School of Law

  • Ph.D. in Molecular Biology and Immunology, Thomas Jefferson University

  • B.S. in Microbiology, Louisiana State University

Admissions

  • Registered Patent Agent, U.S. Patent and Trademark Office

Affiliations

  • Licensing Executive Society (LES)
  • American Intellectual Property Law Association (AIPLA)
  • American Bar Association (ABA)

Presentations

  • “Trends in Paragraph IV Challenges: What Lies Ahead in 2017 and Beyond,” Live Webcast, presented by The Knowledge Group, LLC (May 24, 2017)
  • “The ever-evolving section 101 eligibility criteria in US,” 4th World Intellectual Property Forum, Bangalore, India (April 26-28, 2017)
  • “Functional significance of naturally occurring mutants in HIV-1 Vpr,” The 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA (February 24-28, 2002)
  • “Role of residues 47-52 located between helical domains II and III of HIV-1 Vpr,” The Retroviruses conference, Cold Spring Harbor, NY (May 22-27, 2001)

Publications

Legal Publications

  • “FDA Releases Draft Guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application,” BioLoquitur Life Sciences Blog (December 4, 2017)
  • “Momenta v. Teva – Effective Claiming of Methods of Testing Drug Products,” BioLoquitur Life Sciences Blog (December 21, 2015)
  • “Unraveling the Riddle, Solving the Mystery and Comprehending the Enigma: Amgen Inc. v. Sandoz Inc.,” BioLoquitur Life Sciences Blog (November 3, 2015)
  • “Torrent v. Apotex: Secondary Indicia Insufficient to Counter Obviousness of Gilenya at PTAB,” BioLoquitur Life Sciences Blog (October 13, 2015)

Scientific Publications

  • Co-Author, “The role of Vpr in the regulation of HIV-1 gene expression,” Cell Cycle (2006)
  • Co-Author, “Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication,” Virology (2004)
  • Co-Author, “HIV-1 Vpr: Genetic diversity and functional features from the perspective of structure,”  DNA and Cell Biology (2004)
  • Co-Author, “Role of HIV-1 Vpr in AIDS Pathogenesis: relevance and implications of intravirion, intracellular and free Vpr,” Biomedicine and Pharmacotherapy (2003)
  • Co-Author, “Virion-associated HIV-1 Vpr: Variable amount of virus particles derived from cells upon virus infection of proviral DNA transfection,”  Virology (2001)
  • Co-Author, “Synthesis of N-∝-Boc- benz[f]tryptophan: an intrinsic/extrinsic fluorescence probe,” Pept. Proc. Am. Pept. Symp. (1999)
  • Co-Author, “Benz[f]tryptophan, a bathochromic analog of tryptophan, synthesis of its N-∝-t-Boc derivative,” Tetrahedron Letters (1997)

Accolades

  • Patent Examining Function (Office of Patent Quality Assurance, USPTO), 2006
  • Cancer Research Training Award (National Cancer Institute), 2004-2005
  • Thomas Jefferson University Alumni Travel Fellowship, 2000-2003
  • Research Training Grant in Cancer Immunology (National Cancer Institute), 2000-2003
  • Thomas Jefferson University Foerderer Fellowship, 1998-2000